Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Ear Hear. 2012 Jul;33(4):521–533. doi: 10.1097/AUD.0b013e31824b9dfc

Table 1.

Demographic information for each participant.

Participant Age at Implant Etiology Age at Onset of HL (P/B) Age HA Use Began (P/B) Age HA Use Ended (P) Duration SPHL CI Ear (P) Hearing Aid (B)
P1 45 Unknown 25 / 25 25 / 25 45 1 Widex Diva 19
P2 28 Meniere's 19 / 19 22 / 22 24 1.5 Beltone LINQ
P3 59 Familial 20 / 20 23 / 28 56 10 Phonak Naida V SP
P4 28 Unknown 3 / 3 Never / 3 n/a 25 Unitron Power
P5 28 Unknown/EVA 5* / 23 Never / 28 n/a 23 Starkey S Series
P6 26 Meningitis 7 months Never / 1 n/a 25.5 Widex Inteo 19
P7 77 Unknown 37 / 57 Never / 67 n/a 40 Widex Mind 440
P8 82 Familial/Noise 62 / 62 63 / 77 77 6 Starkey S Series
P9 80 Meniere's/Noise 47 / 25 Never / 63 n/a 34 Phonak Eleva
P10 76 Unknown 61 / 61 69 / 75 72 6 Starkey S Series
*

Possibly congenital

Note: EVA = enlarged vestibular aqueduct; HL = hearing loss; P = poorer hearing ear; B = better hearing ear; HA = hearing aid; SPHL = severe-to-profound hearing loss; CI = cochlear implant